Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biombalance is a proprietary, oligomeric procyanidin-rich grape seed extract (GSE) developed by Euromed as a multifunctional nutraceutical ingredient for gut health and gut-brain axis modulation. It exhibits potent antioxidant, anti-inflammatory, and antibacterial properties. Mechanistically, Biombalance protects intestinal epithelial cells from oxidative damage, inhibits the expression of proinflammatory markers such as IL-6, IL-17, and TNF-α, and selectively modulates the gut microbiota by increasing beneficial taxa like *Bifidobacterium* and *Lactobacillus* while reducing potentially harmful Proteobacteria. Furthermore, it has been shown to influence key gut-brain axis mediators, including GLP-1 and its receptor. Preclinical studies in mice models of colitis have demonstrated its potential to reduce gut inflammation and oxidative stress, partly through modifications of the microbiota and its metabolites.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biombalance.